While we report improved survival outcomes and evidence of an immunomodulatory role of gemcitabine in rectal cancer, this study has limitations, including the small sample size and the lack of information on MSI/MMR status, as well as the lack of comparison with CD8+ and PD-L1+ TIL in the historical standard-of-care control group. This evidence concerns the gene CD274 and rectal cancer.